Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

China flag China · Delayed Price · Currency is CNY
15.21
+0.43 (2.91%)
May 23, 2025, 12:44 PM CST
129.41%
Market Cap 7.06B
Revenue (ttm) 293.05M
Net Income (ttm) -143.41M
Shares Out 477.77M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 43,061,671
Average Volume 35,601,457
Open 10.61
Previous Close 14.78
Day's Range 10.61 - 15.93
52-Week Range 5.41 - 15.78
Beta 0.55
RSI 80.28
Earnings Date Apr 25, 2025

About SHE:300204

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Troponium Chloride Capsules, Gliclazide extended-release ta... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 555
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300204
Full Company Profile

Financial Performance

In 2024, SHE:300204's revenue was 324.82 million, a decrease of -10.81% compared to the previous year's 364.18 million. Losses were -144.84 million, -63.69% less than in 2023.

Financial Statements

News

There is no news available yet.